ProNAi Therapeutics Inc. (NASDAQ:DNAI) shares were up 5.8% during trading on Monday . The stock traded as high as $2.07 and last traded at $2.00, with a volume of 2,656,750 shares changing hands. The stock had previously closed at $1.89.

Several analysts recently weighed in on DNAI shares. Zacks Investment Research downgraded shares of ProNAi Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 15th. Wedbush downgraded shares of ProNAi Therapeutics from an “outperform” rating to a “neutral” rating in a research report on Monday, June 6th. SunTrust Banks Inc. downgraded shares of ProNAi Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $25.00 to $4.00 in a research report on Monday, June 6th. Finally, Jefferies Group downgraded shares of ProNAi Therapeutics from a “buy” rating to a “hold” rating and cut their price objective for the company from $22.00 to $4.50 in a research report on Monday, June 6th.

The company has a 50 day moving average price of $1.98 and a 200-day moving average price of $4.54. The company’s market cap is $60.04 million.

ProNAi Therapeutics (NASDAQ:DNAI) last released its earnings results on Friday, August 12th. The company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by $0.05. Analysts anticipate that ProNAi Therapeutics Inc. will post ($1.32) earnings per share for the current fiscal year.

An institutional investor recently raised its position in ProNAi Therapeutics stock. RS Investment Management Co. LLC increased its stake in shares of ProNAi Therapeutics Inc. (NASDAQ:DNAI) by 12.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 699,794 shares of the company’s stock after buying an additional 76,550 shares during the period. RS Investment Management Co. LLC owned approximately 2.33% of ProNAi Therapeutics worth $10,525,000 as of its most recent filing with the SEC.

ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.